PRMT1 promotes pancreatic cancer growth and predicts poor prognosis
ConclusionsCollectively, our study provides novel insight into the expression and function of PRMT1 in PDAC and indicates that PRMT1 may serve as a therapeutic target for treating patients with pancreatic ductal adenocarcinoma. (Source: Cellular Oncology)
Source: Cellular Oncology - September 13, 2019 Category: Cancer & Oncology Source Type: research

The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma
ConclusionBased on our findings we conclude that inhibition of CD81 suppresses intracellular signaling and reduces tumorigenesis and lung metastasis in osteosarcoma cells. (Source: Cellular Oncology)
Source: Cellular Oncology - September 7, 2019 Category: Cancer & Oncology Source Type: research

Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells
AbstractPurposePancreatic ductal adenocarcinoma (PDAC) is the most common and lethal subtype of pancreatic cancer, with a 5-year survival rate of
Source: Cellular Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

Crosstalk between 14-3-3 θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation
ConclusionsFrom our data we conclude that the scaffold protein 14-3-3 θ enhances the aberrant activity of the chimeric transcription factor MLL-AF4 and, therefore, represents a new player in the molecular pathogenesis of t(4;11)-positive leukemia and a new promising therapeutic target. (Source: Cellular Oncology)
Source: Cellular Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells
ConclusionsOur data support a synergistic effect of PL and oxaliplatin and suggest that application of its combination may be more effective for the treatment of gastric cancer than oxaliplatin alone. (Source: Cellular Oncology)
Source: Cellular Oncology - September 6, 2019 Category: Cancer & Oncology Source Type: research

CD47: role in the immune system and application to cancer therapy
ConclusionsHere, we review the role of CD47 in the maintenance of immune system homeostasis. We also depict three emerging CD47-targeting strategies for cancer therapy, including the use of mimicry peptides, antibodies, and gene silencing strategies. Among these approaches, the most advanced one is the use of anti-CD47 antibodies, which enhances cancer cell phagocytosis via inhibition of the CD47-SIRP α axis. These antibodies can also achieve higher anti-cancer efficacies when combined with chemotherapy and immunotherapy and hold promise for improving the survival of patients with cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - August 14, 2019 Category: Cancer & Oncology Source Type: research

Epigenetics of lung cancer: a translational perspective
ConclusionsA variety of epigenetic modifications do occur at different steps of lung cancer development, some of which are key to tumor progression. The rise of cutting-edge technologies such as single cell epigenomics is, and will continue to be, crucial for uncovering epigenetic events at a single cell resolution, leading to a better understanding of the biology underlying lung cancer development and to the design of novel therapeutic options. This approach has already led to the development of strategies involving single agents or combined agents targeting epigenetic modifiers, currently in clinical trials. Here, we wil...
Source: Cellular Oncology - August 8, 2019 Category: Cancer & Oncology Source Type: research

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications
ConclusionsOverall, tumor dormancy may represent an additional step in the acquisition of cancer characteristics, and its comprehension may clarify both theoretical and practical aspects of cancer development. Clinically, only a deep understanding of dormancy may explain the course of tumor development in different patients, thus representing a process that may be targeted to prevent and/or treat advanced-stage cancers. That is especially the case for breast cancer, against which the mTOR inhibitor everolimus displays potent antitumor activity in patients with metastatic disease by impeding autophagy and tumor dormancy ons...
Source: Cellular Oncology - August 7, 2019 Category: Cancer & Oncology Source Type: research

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment
ConclusionsOur results indicate that PEITC targets HER2-positive CSCs and that its combination with trastuzumab may pave the way for a novel therapeutic strategy for HER2-positive tumors. (Source: Cellular Oncology)
Source: Cellular Oncology - August 2, 2019 Category: Cancer & Oncology Source Type: research

The emerging role of noncoding RNAs in colorectal cancer chemoresistance
ConclusionsIn this review, we highlight the emerging roles and the regulatory mechanisms by which miRNAs and lncRNAs affect CRC chemoresistance. Tumor-specific miRNAs and lncRNAs may serve as novel therapeutic targets and prognostic biomarkers for CRC. (Source: Cellular Oncology)
Source: Cellular Oncology - July 29, 2019 Category: Cancer & Oncology Source Type: research

Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN
ConclusionsFrom our data we conclude that hBMSC-derived exosomes overexpressing miR-34a may be instrumental for the therapeutic targeting and clinical management of GBM. (Source: Cellular Oncology)
Source: Cellular Oncology - July 22, 2019 Category: Cancer & Oncology Source Type: research

Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
ConclusionsFrom our results, we conclude that apatinib suppresses the in vitro and in vivo viability and proliferation of ovarian cancer cells, as well as glycolysis by inhibiting the VEGFR2/AKT1/GSK3 β/SOX5/GLUT4 signaling pathway. Apatinib may serve as a promising drug for the treatment of ovarian cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - July 20, 2019 Category: Cancer & Oncology Source Type: research

QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway
ConclusionOur data indicate that upregulation of GLI1 induced by QKI deficiency maintains GSC stemness and enhances the invasiveness of GBM cells, thereby hinting at new options for the treatment of GBM. (Source: Cellular Oncology)
Source: Cellular Oncology - July 10, 2019 Category: Cancer & Oncology Source Type: research

Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway
ConclusionsPRDX4 reduces anoikis and promotes tumorigenesis and metastasis of HCC cells through stabilization of the β-catenin protein and upregulation of ID2. Targeting of PRDX4 may represent a promising strategy to block HCC cell growth and metastasis. (Source: Cellular Oncology)
Source: Cellular Oncology - June 29, 2019 Category: Cancer & Oncology Source Type: research

The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges
ConclusionsHere, we present published data on the cell- and secretome-based therapeutic competences of MSCs, as well as on their potential as engineered delivery vectors for the treatment of lung cancer. Despite the controversial role of MSCs in the context of lung cancer therapy, current findings support hopeful perspectives to harness the potential of MSC-based regimens that may augment current treatment modalities in lung cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - June 28, 2019 Category: Cancer & Oncology Source Type: research

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
ConclusionsFrom our data we conclude that impairment of the cyclin D-CDK4/6-Rb pathway is a frequent feature of HCC and that it is associated with a unfavourable prognosis. We also found that ribociclib exhibits a preferential antineoplastic activity in Rb-high HCC cells. Our results warrant further investigation of Rb and p16 expression as markers of HCC sensitivity to ribociclib. (Source: Cellular Oncology)
Source: Cellular Oncology - June 27, 2019 Category: Cancer & Oncology Source Type: research

Recent advances in the clinical development of immune checkpoint blockade therapy
ConclusionsHerein, we summarize current knowledge about the role of, and the mechanisms underlying PD-1/PD-L1 signaling pathways in antitumor immune responses, with particular emphasis on clinical studies evaluating the efficacy of anti-PD-1/PD-L1 blockade in various tumor types. Preliminary clinical investigations with immune-checkpoint blockers highlight broad opportunities with a high potential to enhance antitumor immunity and, as such, to generate significant clinical responses. These preliminary successes open up new avenues towards efficient therapeutics offered to patients. (Source: Cellular Oncology)
Source: Cellular Oncology - June 14, 2019 Category: Cancer & Oncology Source Type: research

Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration
ConclusionsFrom our data, we conclude that TAM-derived TNF α induces IL-32β in TC cells. Although IL-32β does not affect TC cell migration, alternative splicing of IL-32 towards the IL-32β isoform may be beneficial for TC cell survival through induction of the pro-survival cytokine IL-8. (Source: Cellular Oncology)
Source: Cellular Oncology - June 14, 2019 Category: Cancer & Oncology Source Type: research

Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction
ConclusionsHere, we describe in detail the interplay between the p53 and HSF1 signaling pathways, with particular emphasis on the molecular mechanisms involved, as well as their importance for normal cellular behavior, cancer development, the effectiveness of anti-cancer therapies and their toxicity. Detailed knowledge of the complex interplay between HSF1 and p53 may form a basis for the design of new protocols for cancer treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - June 10, 2019 Category: Cancer & Oncology Source Type: research

The role of TNF- α in chordoma progression and inflammatory pathways
ConclusionsFrom our data we conclude that TNF- α may serve as a prognostic marker for chordoma progression and that tumor-promoting inflammation may be a major factor in chordoma tumor progression. (Source: Cellular Oncology)
Source: Cellular Oncology - June 7, 2019 Category: Cancer & Oncology Source Type: research

Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway
ConclusionsOur study indicates that cancer cells can revert from apoptosis even after the induction of widespread MOMP. We noted a significant role of the nuclear-export pathway in the anastatic process of cancer cells. Inhibition of anastasis through the nuclear export pathway may be a potential therapeutic strategy for targeting drug-resistance, metastasis and recurrence problems during cancer treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - May 30, 2019 Category: Cancer & Oncology Source Type: research

Tumor-associated macrophages: role in cancer development and therapeutic implications
ConclusionsClinical therapeutic approaches that show most promise include blocking the extravasation of TAMs along with using TAMs as diagnostic biomarkers for cancer progression. The targeting of TAMs in a variety of clinical settings appears to be a promising strategy for decreasing metastasis formation and for improving patient outcome. (Source: Cellular Oncology)
Source: Cellular Oncology - May 29, 2019 Category: Cancer & Oncology Source Type: research

Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy
ConclusionsFrom our data we conclude that post-nCT miR-18a expression in breast cancer serves as a negative prognostic marker, especially in luminal tumors. Clinical, in vitro and in silico data support the role of miR-18a in breast cancer cell proliferation and endocrine resistance and suggest its potential utility as a biomarker for additional adjuvant treatment in patients without a pathologic complete response to neoadjuvant therapy. (Source: Cellular Oncology)
Source: Cellular Oncology - May 21, 2019 Category: Cancer & Oncology Source Type: research

Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial
ConclusionsIn high-risk stage II and stage III colon cancer, we found that subgroup analysis of the combined parameters stromal organization and TSR allows for the identification of patients with absolute cumulative DFS and OS benefits of up to 15%, when adding bevacizumab to the currently recommended oxaliplatin-based chemotherapy. Stromal organization itself does, however, not serve as an independent prognostic or predictive parameter. (Source: Cellular Oncology)
Source: Cellular Oncology - May 17, 2019 Category: Cancer & Oncology Source Type: research

Inhibition of CBP/ β-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells
ConclusionsTargeting Porcupine or the CBP/ β-catenin interaction seems to be an effective strategy for the inhibition of canonical Wnt signaling in HNSCC cells. Further studies are required to confirm the possible therapeutic effect of IWP-2 and PRI-724 in HNSCC. (Source: Cellular Oncology)
Source: Cellular Oncology - May 14, 2019 Category: Cancer & Oncology Source Type: research

The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells
ConclusionsOur findings indicate that dacomitinib-mediated blockade of the ERBB receptors yields advantages over single-targeted ERBB inhibition and provide a rationale for further investigation of the therapeutic potential of dacomitinib in the treatment of ERBB-driven PDAC. (Source: Cellular Oncology)
Source: Cellular Oncology - April 25, 2019 Category: Cancer & Oncology Source Type: research

Hypo-phosphorylated CD147 promotes migration and invasion of hepatocellular carcinoma cells and predicts a poor prognosis
ConclusionsFrom our data we conclude that hypo-phosphorylated CD147 promotes the migration and invasion of HCC cells and correlates with an unfavorable prognosis in HCC patients, indicating that targeting the aberrantly hypo-phosphorylated form of CD147 may be instrumental for the development of novel therapeutic modalities directed against HCC metastasis. (Source: Cellular Oncology)
Source: Cellular Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells
ConclusionsBased on our data we conclude that we have identified a novel interaction between M2-type TAMs and HNSCC cells that contributes to gefitinib resistance. We also found that metformin inhibited the cross-talk between macrophages and tumor cells, thereby eliciting therapeutic effects both in vitro and in vivo. (Source: Cellular Oncology)
Source: Cellular Oncology - April 17, 2019 Category: Cancer & Oncology Source Type: research

The role of caveolin-1 in tumors of the brain - functional and clinical implications
ConclusionsCav-1 has the potential to pivot the molecular basis underlying the pathobiology of brain tumors, particularly the malignant glial subtype. In addition, the regulatory effect of cav-1-dependent and caveola-mediated transcellular transport on the permeability of the blood tumor barrier could be of benefit to overcome the restricted transport across brain barriers when applying chemotherapeutics. The association of cav-1 with tumors of the brain other than malignant gliomas deserves to be underlined, as well given the evidence suggesting its potential in predicting tumor grade and recurrence rates together with de...
Source: Cellular Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Deep learning and manual assessment show that the absolute mitotic count does not contain prognostic information in triple negative breast cancer
ConclusionsBased on our results we conclude that the level of proliferation, as reflected by mitotic count, does not serve as a prognostic factor for TNBC. Therefore, TNBC patient management based on mitotic count should be discouraged. (Source: Cellular Oncology)
Source: Cellular Oncology - April 15, 2019 Category: Cancer & Oncology Source Type: research

The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells
ConclusionsOur data indicate that FOXO3a activation is a crucial event in the response of GBM cells to EGFR inhibition, suggesting that FOXO3a may serve as an actionable therapeutic target that can be modulated using FDA-approved drugs. (Source: Cellular Oncology)
Source: Cellular Oncology - April 13, 2019 Category: Cancer & Oncology Source Type: research

Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition
ConclusionsIn this review, we summarize the mechanisms by which curcumin may affect EMT in cells under pathological conditions to understand its potential as a novel anti-tumor agent. Curcumin can exert chemo-preventive effects by inhibition and reversal of the EMT process through both TGF- β-dependent (e.g. in hepatoma and retinal pigment epithelial cancer) and -independent (e.g. in oral cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, breast cancer, melanoma, prostate cancer, bladder cancer, thyroid cancer and lung cancer) pathways. Curcumin can also mitigate chemoresistance through EMT suppre...
Source: Cellular Oncology - April 13, 2019 Category: Cancer & Oncology Source Type: research

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
ConclusionsThe first DLL3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T, SC16LD6.5) has shown promising results in terms of efficacy and safety for the management of extensive SCLC, supporting further studies on this novel therapeutic approach that combines specific SCLC targeting with the cell-killing ability of a pyrrolobenzodiazepine dimer. In the present review, we discuss currently available evidence on the biological role of Notch signaling in SCLC from early preclinical findings to current and future clinical implications. (Source: Cellular Oncology)
Source: Cellular Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research

IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells
ConclusionsFrom our data we conclude that IFITM3 is overexpressed in OSCC and may regulate the CCND1-CDK4/6-pRB axis to mediate OSCC cell growth. (Source: Cellular Oncology)
Source: Cellular Oncology - April 4, 2019 Category: Cancer & Oncology Source Type: research

ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein
ConclusionsThese results provide evidence that ABT-263 may serve as an effective therapeutic agent for the treatment of human oral cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - March 27, 2019 Category: Cancer & Oncology Source Type: research

Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report
ConclusionThrough gene co-expression network analysis and subsequent functional analyses we identified hub gene CDC45 as a putative novel therapeutic target in NSCLC. (Source: Cellular Oncology)
Source: Cellular Oncology - March 18, 2019 Category: Cancer & Oncology Source Type: research

Leptin-induced signaling pathways in cancer cell migration and invasion
ConclusionsIn this review, we describe metastasis steps in detail and characterize metastasis-related molecules activated by leptin, which may help to develop a roadmap that guides future work. In addition, we conclude that a profound understanding of the fundamental molecular processes that contribute to leptin-induced metastasis may pave the way for the development of new prognostic molecules and appropriate approaches to the treatment of obesity-related cancers. (Source: Cellular Oncology)
Source: Cellular Oncology - March 15, 2019 Category: Cancer & Oncology Source Type: research

Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis
ConclusionsOur data indicate that concomitant inhibition of RAC1 and Bcl-2/Bcl-xL induces pro-apoptotic and anti-migratory glioblastoma phenotypes as well as synergistic anti-neoplastic activities. The clinical efficacy of this inhibitory therapeutic strategy warrants further evaluation. (Source: Cellular Oncology)
Source: Cellular Oncology - March 11, 2019 Category: Cancer & Oncology Source Type: research

The significance of cytokine-producing B cells in breast tumor-draining lymph nodes
AbstractPurposeThe role of cytokine-producing B cells in antitumor immunity is mostly overlooked. In the present study, we investigated changes in B cell cytokine profiles in breast tumor-draining lymph nodes (TDLNs) during disease progression, and associations of these changes with prognostic indicators.MethodsFlow cytometry was used to measure the expression of TNF- α, IL-10, TGF-β, IL-2 and IFN-γ in B cells from 42 axillary lymph nodes. The frequencies of IL-10+ and FoxP3+ T regulatory cells (Tregs) were also determined.ResultsNo significant changes in B cell cytokine profiles were observed during breas...
Source: Cellular Oncology - March 8, 2019 Category: Cancer & Oncology Source Type: research

Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content – a short report
ConclusionsThe present study confirms a poor outcome of patients with stroma-high tumours. Low CDX2 expression in tumours with a high stromal content identified patients with a particularly poor prognosis. The present study did not reveal a clear difference in TSR associated with CDX2 status and survival. This method, solely based on microscopy, identifies patients who have a high risk of relapse and a poor outcome, and who may benefit from targeted therapy. (Source: Cellular Oncology)
Source: Cellular Oncology - March 8, 2019 Category: Cancer & Oncology Source Type: research

CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification
ConclusionsFrom our data, we conclude that THZ1 may effectively control the proliferation and survival ofSOX2-amplified SCC cells through a decrease in global transcriptional activity, suggesting that CDK7 inhibition leading to transcription suppression may be a promising therapeutic option for lung SCC with aSOX2 amplification. (Source: Cellular Oncology)
Source: Cellular Oncology - March 5, 2019 Category: Cancer & Oncology Source Type: research

SNHG6 is upregulated in primary breast cancers and promotes cell cycle progression in breast cancer-derived cell lines
ConclusionsOur results indicate that lncRNA SNHG6 is involved in breast cancer development and may be considered as a potential biomarker for the diagnosis, prognosis and treatment of breast cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - March 2, 2019 Category: Cancer & Oncology Source Type: research

Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer
ConclusionsThis work shows that TSR is an independent prognosticator in rectal cancer when assessed automatically in user-provided stroma hot-spots. The deep learning-based technology presented here may be a significant aid to pathologists in routine diagnostics. (Source: Cellular Oncology)
Source: Cellular Oncology - March 1, 2019 Category: Cancer & Oncology Source Type: research

Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients
ConclusionFrom our data we conclude that CD45RO+ TILs serve as prognostic factors for predicting OS and DFS of breast cancer patients. (Source: Cellular Oncology)
Source: Cellular Oncology - March 1, 2019 Category: Cancer & Oncology Source Type: research

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma
ConclusionsOur results indicate that elevated glycolytic activity is associated with NHL aggressiveness, pointing at metabolic cooperation, mediated by MCT1 and MCT4, between tumour cells and their surrounding stroma. MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours. Further (pre-)clinical studies are required to allow the design of novel therapeutic strategies aimed at e.g. reprogramming the tumour microenvironment. (Source: Cellular Oncology)
Source: Cellular Oncology - February 21, 2019 Category: Cancer & Oncology Source Type: research

Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation
ConclusionsCollectively, our data indicate that trametinib exhibits efficacy in treating HCC cells via distinct regulation of the MYC and BIM pathways. As such, targeting MEK to block MAPK signaling with trametinib may provide novel treatment opportunities for HCC. (Source: Cellular Oncology)
Source: Cellular Oncology - February 20, 2019 Category: Cancer & Oncology Source Type: research

The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival
ConclusionFrom our data we conclude that XIAP acts as a multifunctional pro-metastatic protein in skin melanomas and, as a consequence, that XIAP may serve as a therapeutic target for these melanomas. (Source: Cellular Oncology)
Source: Cellular Oncology - February 18, 2019 Category: Cancer & Oncology Source Type: research

Secretome profiling of heterotypic spheroids suggests a role of fibroblasts in HIF-1 pathway modulation and colorectal cancer photodynamic resistance
ConclusionCollectively, our results delineate a potential mechanism by which stromal fibroblasts may enhance colorectal cancer cell survival and photodynamic treatment resistance via HIF-1 pathway modulation. (Source: Cellular Oncology)
Source: Cellular Oncology - February 12, 2019 Category: Cancer & Oncology Source Type: research

Antitumor effect of XCT790, an ERR α inverse agonist, on ERα-negative endometrial cancer cells
AbstractPurposeThe estrogen-related receptor (ERR) α is structurally similar to classical estrogen receptors (ERs), but is considered to be an orphan nuclear receptor. We previously found that ERRα regulates uterine endometrial cancer progression. Here, we investigated the efficacy of XCT790, a selective inverse agonist of ERRα, on endometrial ca ncer cells in vitro and in vivo.MethodsHEC-1A and KLE, ER α-negative endometrial cancer cells exhibiting high ERRα expression levels, and HEC-1A cell-derived xenograft model mice were treated with XCT790. Transcriptional activity and cell proliferatio...
Source: Cellular Oncology - January 31, 2019 Category: Cancer & Oncology Source Type: research

Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion
ConclusionsOur data suggest that the developed cell-permeable R10-HOXA9 system may serve as a useful tool to prevent NSCLC cell migration and invasion. (Source: Cellular Oncology)
Source: Cellular Oncology - January 29, 2019 Category: Cancer & Oncology Source Type: research